Baxter International Under Legal Fire for Novum LVP Product Defects and Investor Misleading
- Baxter International is facing a class action lawsuit over undisclosed defects in its Novum LVP product.
- Allegations include misleading investors about product safety and failing to address critical malfunctions affecting patient health.
- Shareholders can register for lead plaintiff status by December 15, 2025, to seek potential compensation.
Baxter International Faces Legal Scrutiny Over Novum LVP Product Defects
Baxter International, Inc. is currently under legal scrutiny as The Gross Law Firm issues a notice to shareholders regarding potential lead plaintiff appointments in a class action lawsuit. The lawsuit stems from allegations that Baxter misled investors by failing to disclose critical defects in its Novum LVP (Large Volume Parenteral) product. These issues reportedly lead to dangerous malfunctions, including underinfusion, overinfusion, and complete fluid delivery failures, which pose serious health risks for patients. The class period for the lawsuit is defined as being from February 23, 2022, to October 29, 2025, allowing shareholders who purchased shares within this timeframe to seek potential compensation if the allegations are proven true.
The lawsuit claims that Baxter was aware of multiple malfunctions related to the Novum LVP devices, as well as associated injuries and fatalities, yet it failed to adequately address these issues. According to the allegations, the company provided insufficient customer alerts regarding the risks, which not only jeopardized patient safety but also increased the likelihood of existing devices being withdrawn from service. Furthermore, the lawsuit asserts that Baxter's public communications about the safety, efficacy, and sales outlook of the Novum LVPs were materially false and misleading, leading shareholders to believe that the product was safe and reliable when, in fact, it was not.
Shareholders are urged to register for the class action lawsuit before the December 15, 2025, deadline to seek lead plaintiff status. This registration grants access to portfolio monitoring software that provides updates on the case's progress, and participants incur no costs or obligations. The Gross Law Firm, recognized for its focus on protecting investors' rights against corporate misconduct, emphasizes the importance of addressing deceptive practices within the healthcare industry, particularly when patient safety is at stake.
In light of these developments, Baxter International must navigate not only the legal ramifications of the lawsuit but also the reputational damage that comes from allegations of negligence in the safety of its medical devices. The outcome of this case could have significant implications for the company's future operations and its commitment to patient safety standards. As the situation unfolds, stakeholders and the public closely monitor how Baxter responds to these serious allegations and whether it takes decisive action to rectify the reported issues with its Novum LVP product line.
Related Cashu News

Merit Medical Systems Launches Employee Stock Ownership Plan to Boost Engagement and Stability
Merit Medical Systems (Ticker: MMSI) recently takes a significant step in enhancing its employee engagement and ownership structure with the launch of a new Employee Stock Ownership Plan (ESOP). The c…

Brookdale Senior Living launches second season of educational podcast "The Grey Take.
Brookdale Senior Living (Ticker: BKD) launches the second season of its popular podcast, "The Grey Take," which serves as a valuable resource for families exploring senior living options. The podcast…

Molina Healthcare Gains Momentum with Increased Risk Adjustment Payments and Positive Revenue Outlook
Molina Healthcare (Ticker: MOH) is making significant strides in its revenue outlook due to recently released risk adjustment figures from the Centers for Medicare & Medicaid Services (CMS). These upd…

Align Technology Faces Antitrust Investigation by European Commission Over Competitive Practices
Align Technology Inc. (Ticker: ALGN) faces a formal antitrust investigation from the European Commission, marking a significant development in the medical devices sector. This inquiry arises from a co…

